The 100% tariff on imported branded pharma is not applicable to Indian pharmaceutical companies as majority of the players deal in generic drugs,” said Vikas Gupta, CEO & chief investment strategist, OmniScience Capital. “Fears that it could also pertain to all kinds of products led to the decline.
